Top Markets
Coin of the day
Medesis Pharma S.A. Medesis Pharma S.A.

Medesis Pharma S.A.

ALMDP
Clasificación en acciones #37493
Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development... Medesis Pharma S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to creating orally delivered molecular drug therapies aimed at critical medical conditions lacking effective treatments. The company's pipeline features several innovative compounds, including NanoLithium (NP03), which is currently undergoing clinical trials for Alzheimer's disease, and NanosiRNA DH, targeting Huntington's Disease. Medesis Pharma also develops NU01 Plutonium and NU02 Cesium for nuclear decorporation, alongside NP02 – NanoManganese, a radioprotection medication designed for individuals exposed to radiation from nuclear incidents. Furthermore, their portfolio encompasses NanosiRNA COVID-19, an antiviral solution for various viral infections, and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for oncological applications. Established in 2003, the enterprise operates from its headquarters in Montpellier, France.
Precio por acción
$0.38207938
Última sincronización: 2025-04-07
Capitalización bursátil
$1.67M
Cambio (1 día)
-0.39%
Cambio (1 año)
0.00%
País
FR
Comercio Medesis Pharma S.A. (ALMDP)

Categoría

Ratio P/B de Medesis Pharma S.A. (ALMDP)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Medesis Pharma S.A., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Medesis Pharma S.A. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE